IL13 and asthma: The presumed role of IL-13 in asthma led to the clinical development of anti–IL-13 treatment strategies such as tralokinumab, an immunoglobulin (Ig) G4 human monoclonal antibody (mAb) that potently and specifically neutralises IL-13 by preventing its interaction with the IL-13 receptor α1 and α2 subunits [10, 11].